Agonisty dofaminovykh retseptorov – preparaty vybora terapii rannikh stadiy bolezni Parkinsona


Cite item

Full Text

Abstract

При выборе противопаркинсонического препарата учитывают многие факторы: возраст больного, степень тяжести заболевания, наличие или отсутствие когнитивных расстройств, сопутствующие заболевания, стоимость лечения, социально-экономические факторы. Традиционно терапия ранних стадий начинается с назначения агонистов дофаминовых рецепторов (АДАР), амантадинов, реже ингибиторов моноаминоксидазы (МАО), холинолитиков.

About the authors

N. V Fedorova

РМАПО; Центр экстрапирамидных заболеваний МЗ и СР РФ, Москва

Кафедра неврологии

References

  1. Артемьев Д.В., Обухова А.В. Современные подходы к лечению ранних стадий болезни Паркинсона. Consilium Medicum 2008; 10 (7): 89–92.
  2. Левин О.С. Агонисты дофаминовых рецепторов в лечении болезни Паркинсона. Леч. нервн. бол. 2003; 4 (1): 14–7.
  3. Нодель М.Р., Артемьев Д.В., Яхно Н.Н. Эффективность дофаминового агониста мирапекса при болезни Паркинсона. Неврол. журн. 1999; 6 (4): 45–9.
  4. Федорова Н.В., Кулуа Т.К. Опыт применения прамипексола в лечении болезни Паркинсона. Consilium Medicum 2007; 9 (2): 103–7.
  5. Федорова Н.В., Смоленцева И.Г., Левин О.С. Применение агонистов дофаминовых рецепторов при болезни Паркинсона. Рус. мед. журн. 2000; 8 (15): 643–7.
  6. Chaudhuri K.R, Healy D.G, Schapira A.H. National Institute for Clinical Exellene. Non - motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235–45.
  7. Corrigan M.H, Denahan A.Q, Wright C.E, Ragual R.J. Comparison of pramipexole, fluoxetini, and placebo in patients with major depression. Depress. Anxiety 2000; 11: 58–65.
  8. Fhan S, Oakes O, Shoulson I et al. Levodopa and progression of Parkinson's disease. N. Engl J Med 2004; 351: 2498–508.
  9. Goetz C.G. Dopaminergic agonists in the treatment of Parkinson's disease. Neurology 1990; 40 (Suppl. 3): 50–4.
  10. Goetz C.G, Blasucci L, Stebbins G.T. Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow? Neurology 1999; 52: 1227–9.
  11. Goldberg J.F, Frye M.A, Dunn R.T. Pramipexole in refractory bipolar depression. Am J Psychiatry 1999; 156: 798.
  12. Hauzer R, Reider C, Stacey M et al. Acute versus gradual pramipexole to ropinirile switch. Mov Disord 2000; 15 (Suppl. 3): 133.
  13. Holloway R.G, Shoulson I, Kieburts K et al. Pramipexole vs. levodopa as initial treatment for Parkinson's disease – a 4-year randomized controlled trial. Arch Neurol 2004; 61: 1044–53.
  14. Jenner P. The MPTP - treated primate as a model of motor complications. Neurology 2003; 61 (Suppl. 3): 4–11.
  15. Junghanns S, Glockler T, Reichmann H. Switching and combing of dopamine agonists. J Neurol 2004; 251 (Suppl. 6): 19–23.
  16. Junghanns S., Glockler T., Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004; 251 (Suppl. 6): 19–23.
  17. King D.F, Cooper J.M, Schapira A.H. Pramipexole protects against MPP+toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential. Neurology 2001; 56: 377–88.
  18. Lang A.E. Are the new dopamine agonists better than the old ones? 6th International congress of Parkinson's disease and movement disorders Barcelona, Spain, 2000.
  19. Lemke M.R, Brecht H.M, Koester J еt al. Anhgedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neurops Clin Neurosc 2005; 17: 214–20.
  20. Lev N, Dialdetti R, Melamed E. Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists vs. levodopa. J Neurol 2007; 254 (suppl. 5): 19–26.
  21. Linazasoro G. Conversion from dopamine agonists to pramipexole. J Neurol 2004; 251: 335–9.
  22. Molho E.S, Factor S.A, Weiner W.J et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm 1995; 45 (Suppl): 225–30.
  23. Navan P, Findley L.J, Pearce R.G et al. A randomly assigned double - blind cross - over study examining the relative anti - parkinsonian tremor effects of pramipexole and pergolide. Eur J Neurol 2005; 12 (1): 1–8.
  24. Noyes K, Dick A, Holloway R.G. and the Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomized clinical - economic trail. Med Decis Making 2004; 24: 472–85.
  25. Oertel W.H. Pergolide vs Levodopa (PELMOPET). Mov Disord 2000; 15 (Suppl. 3): 86.
  26. Oertel W.H, Wolters E, Sampaio C еt al. Pergolide vs. levodopa monotherapy in early Parkinson's disease patients: PELMOPET study. Mov Disord 2006; 21: 343–53.
  27. Olanov C.W, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson's disease:current controversies. Mov Disord 2004; 19: 997–1005.
  28. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease:A randomized controlled trial. JAMA 2000; 284: 1931–8.
  29. Рarkinson Study Group. A randomized controlled trial comparing Pramipexole with Levodopa in early Parkinson's disease: design and methods of the CALM-PD study. J Clin Neuropharmakol 2000; 23 (1): 34–44.
  30. Pogarell O, Gasser T, Hilten J et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomized, double - blind study, placebo controlled multicenter study. J Neurol Neurosurg Psychiatry 2002; 72: 713–20.
  31. Pogarell O, Gasser T, van Hilten J et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomized, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72: 713–20.
  32. Rajput A.H. Adverse effects of ergot - derivative dopamine agonists. Eds: C.Olanow, J.Obeso. Dopamine agonists in early Parkinson's disease. Kent, – UK: Wells Medical 1997; 209–16.
  33. Rascol O, Brooks D.J, De Deyn P et al. Five - year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl Med 2000; 342: 1484–91.
  34. Rascol O, Rayoux P, Ferreira J et al. The management of patients with early Parkinson's didease. Parkinonism Relat Disord 2002; 9: 61–7.
  35. Reichmann H, Odin P, Brecht H.M et al. Changing dopamine agonist treatment in Parkinson's disease: experience with switching to pramipexole. J Neural Transm 2006; 71 (Suppl.): 17–25.
  36. Samii A, Nutt J.G, Ranson B.R. Parkinson's disease. Lancet 2004; 363: 1783–94.
  37. Schapira A.H. Neuroprotection and dopamine agonists. Neurology; 58 (Suppl. 1): 9–18.
  38. Schapira A.H, Hsu H.H, Scrine K et al. PROUD: The impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. Mov Disor 2008; 23 (Supp. 1): 194.
  39. Schapira A.H, Obeso J. Timing of treatment initiation in Parkinson' disease: a need for reappraisal? Ann Neurol 2006; 59: 562–4.
  40. Stocchi F, Berardelli A, Vacca L et al. Combination of two different dopamine agonists in the management of Parkinson's disease. Neurol Sci 2002; 23 (Suppl. 2): 115–6.
  41. Takahashi H, Nogawa S, Tachibana J et al. Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching. J Int Med Res 2008; 36 (1): 106–14.
  42. Tatton W.G, Ju W.Y.H, Wadia J et al. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. Eds. C.Olanov, P.Jenner, M.Youim. Neurodegeneration and neuroprotection in Parkinson's disease. London: Academic Press 1996; 202–20.
  43. Thomas A, Bonanni L, Di Lorio A et al. End - of - dose deterioration in non ergolinic dopamine agonist monoterapy of Parkinson's disease. J Neurol 2006; 253: 1633–9.
  44. Uitti R.J, Ahlskog J.E. Comparative review of dopamine receptor agonists in Parkinson's disease. Drugs 1996; 5: 369–88.
  45. Wolters E.C, Tissingh G, Bergmans P.L.M et al. Dopamine agonists in Parkinson's disease. Neurology. 1995; 45 (Suppl. 3): 28–34.

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies